Clinical Trials of HAE Therapies

CSL Behring has recently sponsored two studies, one of which, I.M.P.A.C.T. 1, is now closed. Both have used human C1-INH concentrate to treat acute attacks of HAE, which has been used to treat HAE patients in Europe for more than two decades.

• I.M.P.A.C.T. 1: Used human C1-INH concentrate in acute attacks of the abdomen or face in people with type I HAE
• I.M.P.A.C.T. 2: Uses human C1-INH concentrate in acute attacks in people with type I HAE

I.M.P.A.C.T. 1 was a "double-blind" study. In a double-blind study, some subjects receive placebo and some receive medication, but neither the subjects nor the investigator know which patients receive which medications. However, this does NOT mean that those in the placebo group never receive C1-INH.

I.M.P.A.C.T. 2 is not a blinded study, but an "open-label" study. All subjects receive the human C1-INH. Moreover, unlike the I.M.P.A.C.T. 1 study, the medication can be used for different types of attacks.

Patients who meet the eligibility requirements for participation in the study are encouraged to consider this option and have the opportunity to take a more active role in the management of their own health care